Secretase inhibitors and modulators for Alzheimer's disease treatment
- PMID: 19402777
- DOI: 10.1586/ern.09.24
Secretase inhibitors and modulators for Alzheimer's disease treatment
Abstract
Genetic and biological studies provide strong evidence that the deposition of amyloid-beta peptide (Abeta) contributes to the etiology of Alzheimer's disease (AD). Abeta is generated from amyloid-beta precursor protein by beta- and gamma-secretases, which are plausible molecular targets for AD treatment. Thus, drugs that regulate the production of Abeta by inhibiting or modulating secretase activity could provide effective therapeutics for AD. Both secretases are transmembrane proteases: beta-site amyloid-beta precursor protein cleaving enzyme 1, the main neuronal beta-secretase, is a single span transmembrane aspartyl protease; gamma-secretase is a multiprotein complex comprising four core subunits that are all transmembrane proteins: presenilin, nicastrin, anterior pharynx-defective 1 and presenilin enhancer 2. Molecular biochemical, enzymological and genetic analyses reveal the molecular mechanisms of these secretases in the generation of Abeta. Moreover, extensive drug screening and development have enabled some secretase inhibitors and modulators to advance into late-Phase clinical trials. This review focuses on recent progresses in beta- and gamma-secretase biology, including the proteolytic mechanism, regulation and composition of these enzymes. Moreover, this review discusses the recent development of inhibitors, and provides a direction for the effective treatment of AD through inhibition/modulation of beta- and gamma-secretase activities.
Similar articles
-
Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.J Neurochem. 2009 Jul;110(1):275-83. doi: 10.1111/j.1471-4159.2009.06131.x. Epub 2009 Apr 29. J Neurochem. 2009. PMID: 19457123
-
The structure and function of Alzheimer's gamma secretase enzyme complex.Crit Rev Clin Lab Sci. 2009;46(5-6):282-301. doi: 10.3109/10408360903335821. Crit Rev Clin Lab Sci. 2009. PMID: 19958215 Review.
-
CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production.Proc Natl Acad Sci U S A. 2005 May 24;102(21):7499-504. doi: 10.1073/pnas.0502768102. Epub 2005 May 12. Proc Natl Acad Sci U S A. 2005. PMID: 15890777 Free PMC article.
-
Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.J Med Chem. 2009 Oct 22;52(20):6169-88. doi: 10.1021/jm900188z. J Med Chem. 2009. PMID: 19694467 Review. No abstract available.
-
[Therapy of Alzheimer disease].Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Neuropsychopharmacol Hung. 2009. PMID: 19731816 Review. Hungarian.
Cited by
-
Structure-Based Peptide Design to Modulate Amyloid Beta Aggregation and Reduce Cytotoxicity.PLoS One. 2015 Jun 12;10(6):e0129087. doi: 10.1371/journal.pone.0129087. eCollection 2015. PLoS One. 2015. PMID: 26070139 Free PMC article.
-
Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1.EMBO J. 2011 Oct 14;30(23):4815-24. doi: 10.1038/emboj.2011.372. EMBO J. 2011. PMID: 22002539 Free PMC article.
-
Structural Analysis of the Simultaneous Activation and Inhibition of γ-Secretase Activity in the Development of Drugs for Alzheimer's Disease.Pharmaceutics. 2021 Apr 8;13(4):514. doi: 10.3390/pharmaceutics13040514. Pharmaceutics. 2021. PMID: 33917979 Free PMC article.
-
BACE1 activity is modulated by cell-associated sphingosine-1-phosphate.J Neurosci. 2011 May 4;31(18):6850-7. doi: 10.1523/JNEUROSCI.6467-10.2011. J Neurosci. 2011. PMID: 21543615 Free PMC article.
-
Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials.Biomed Res Int. 2014;2014:837157. doi: 10.1155/2014/837157. Epub 2014 Jul 17. Biomed Res Int. 2014. PMID: 25136630 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical